Goldridge Terminal Logo Goldridge Terminal
Popular
Login

Add to Watchlist
Pro Chart

Galmed Pharmaceuticals Lt...

NasdaqCM: GLMD · Real-Time Price · USD
0.55
-0.01 (-1.79%)
At close: Aug 12, 2026, 12:18 PM

Galmed Pharmaceuticals Ltd. (GLMD) Stock Price, Analysis & Data

-1.79%
Bid0.39
Market Cap4.55M
Revenue (ttm)n/a
Net Income (ttm)-11.12M
Beta0.68
EPS (ttm)-2.06
PE Ratio (ttm)n/a
Forward PE-0.53
P/B (ttm)0.26
P/S (ttm)n/a
Earnings Daten/a
Ask0.72
Volume25,959
Avg. Volume (20D)770,508
Open0.57
Previous Close0.56
Day's Range0.55 - 0.57
52-Week Range0.41 - 1.65
Analystn/a
Price Targetn/a
Dividendsn/a
Ex-Dividend Daten/a

About GLMD

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The comp...

[Read more]
Industry Biotechnology
Sector Healthcare
IPO Date Mar 13, 2014
Employees 3
Stock Exchange NasdaqCM
Ticker Symbol GLMD
Website https://galmedpharma.com
Full Company Profile

Financial Performance

In 2025, Galmed Pharmaceuticals's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -10.31M, an increase of 37.14%.

Financial Statements

Earnings Surprise

Galmed Pharmaceuticals has released their quarterly earnings on Jul 8, 2026:
  • Revenue of $0 misses estimates by $0, with NaN% YoY growth.
  • EPS of -0.29 exceeds estimates by 0.09, with 53.23% YoY growth.
    news image

    3 weeks ago · InvestorsHub

    Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD)

    Galmed announced the development of a lipid nanoparticle formulation of Aramchol designed to target heart tissue, marking a potential expansion of the drug beyond its existing liver and gastrointestin...

    news image

    8 months ago · Associated Press Finance

    Galmed Pharmaceuticals: Q3 Earnings Snapshot

    RAMAT GAN, Israel (AP) — Galmed Pharmaceuticals Ltd. (GLMD) on Wednesday reported a loss of $1.9 million in its third quarter. The Ramat Gan, Israel-based company said it had a loss of 33 cents per sh...

    news image

    8 months ago · Associated Press Finance

    BC-Most Active Stocks

    HIVE Digital Technologies Ltd. 30,450,329 3.7899

    news image

    11 months ago · Associated Press Finance

    Galmed Pharmaceuticals: Q2 Earnings Snapshot

    RAMAT GAN, Israel (AP) — Galmed Pharmaceuticals Ltd. (GLMD) on Thursday reported net income of $2.5 million in its second quarter. On a per-share basis, the Ramat Gan, Israel-based company said it had...